Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 234

1.

Phase I to II study of pleurectomy/decortication and intraoperative intracavitary hyperthermic cisplatin lavage for mesothelioma.

Richards WG, Zellos L, Bueno R, Jaklitsch MT, Jänne PA, Chirieac LR, Yeap BY, Dekkers RJ, Hartigan PM, Capalbo L, Sugarbaker DJ.

J Clin Oncol. 2006 Apr 1;24(10):1561-7.

PMID:
16575008
2.

A phase I study of extrapleural pneumonectomy and intracavitary intraoperative hyperthermic cisplatin with amifostine cytoprotection for malignant pleural mesothelioma.

Zellos L, Richards WG, Capalbo L, Jaklitsch MT, Chirieac LR, Johnson BE, Bueno R, Sugarbaker DJ.

J Thorac Cardiovasc Surg. 2009 Feb;137(2):453-8. doi: 10.1016/j.jtcvs.2008.07.055.

3.

Extrapleural pneumonectomy followed by intracavitary intraoperative hyperthermic cisplatin with pharmacologic cytoprotection for treatment of malignant pleural mesothelioma: a phase II prospective study.

Tilleman TR, Richards WG, Zellos L, Johnson BE, Jaklitsch MT, Mueller J, Yeap BY, Mujoomdar AA, Ducko CT, Bueno R, Sugarbaker DJ.

J Thorac Cardiovasc Surg. 2009 Aug;138(2):405-11. doi: 10.1016/j.jtcvs.2009.02.046.

4.

Morbidity, mortality, mean survival, and the impact of histology on survival after pleurectomy in 64 patients with malignant pleural mesothelioma.

Neragi-Miandoab S, Richards WG, Sugarbaker DJ.

Int J Surg. 2008 Aug;6(4):293-7. doi: 10.1016/j.ijsu.2008.04.004. Epub 2008 May 1.

5.
6.

Hyperthermic intraoperative pleural cisplatin chemotherapy extends interval to recurrence and survival among low-risk patients with malignant pleural mesothelioma undergoing surgical macroscopic complete resection.

Sugarbaker DJ, Gill RR, Yeap BY, Wolf AS, DaSilva MC, Baldini EH, Bueno R, Richards WG.

J Thorac Cardiovasc Surg. 2013 Apr;145(4):955-63. doi: 10.1016/j.jtcvs.2012.12.037. Epub 2013 Feb 21.

7.

A phase II study of intrapleural immuno-chemotherapy, pleurectomy/decortication, radiotherapy, systemic chemotherapy and long-term sub-cutaneous IL-2 in stage II-III malignant pleural mesothelioma.

Lucchi M, Chella A, Melfi F, Dini P, Ambrogi M, Fino L, Fontanini G, Mussi A.

Eur J Cardiothorac Surg. 2007 Mar;31(3):529-33; discussion 533-4. Epub 2006 Dec 26.

PMID:
17188885
8.

Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients.

Flores RM, Pass HI, Seshan VE, Dycoco J, Zakowski M, Carbone M, Bains MS, Rusch VW.

J Thorac Cardiovasc Surg. 2008 Mar;135(3):620-6, 626.e1-3. doi: 10.1016/j.jtcvs.2007.10.054. Epub 2008 Feb 14.

9.

Malignant pleural mesothelioma: clinicopathologic and survival characteristics in a consecutive series of 394 patients.

Borasio P, Berruti A, Billé A, Lausi P, Levra MG, Giardino R, Ardissone F.

Eur J Cardiothorac Surg. 2008 Feb;33(2):307-13. doi: 10.1016/j.ejcts.2007.09.044.

PMID:
18164622
10.

Aggressive multimodality therapy for malignant pleural mesothelioma.

Rice TW, Adelstein DJ, Kirby TJ, Saltarelli MG, Murthy SR, Van Kirk MA, Wiedemann HP, Weick JK.

Ann Thorac Surg. 1994 Jul;58(1):24-9.

PMID:
7518666
11.

Treatment of primary peritoneal mesothelioma by continuous hyperthermic peritoneal perfusion (CHPP).

Park BJ, Alexander HR, Libutti SK, Wu P, Royalty D, Kranda KC, Bartlett DL.

Ann Surg Oncol. 1999 Sep;6(6):582-90.

PMID:
10493628
12.

Innovative therapies: intraoperative intracavitary chemotherapy.

Chang MY, Sugarbaker DJ.

Thorac Surg Clin. 2004 Nov;14(4):549-56. Review.

PMID:
15559062
13.
14.

Malignant pleural mesothelioma: surgical management in 285 patients.

Schipper PH, Nichols FC, Thomse KM, Deschamps C, Cassivi SD, Allen MS, Pairolero PC.

Ann Thorac Surg. 2008 Jan;85(1):257-64; discussion 264.

PMID:
18154820
15.

Surgery followed by intracavitary plus systemic chemotherapy in malignant pleural mesothelioma.

Colleoni M, Sartori F, Calabro F, Nelli P, Vicario G, Sgarbossa G, Gaion F, Bortolotti L, Toniolo L, Manente P.

Tumori. 1996 Jan-Feb;82(1):53-6.

PMID:
8623505
16.

The importance of surgical staging in the treatment of malignant pleural mesothelioma.

Rusch VW, Venkatraman E.

J Thorac Cardiovasc Surg. 1996 Apr;111(4):815-25; discussion 825-6.

17.

Hyperthermic pleural perfusion with cisplatin: early clinical experience.

Yellin A, Simansky DA, Paley M, Refaely Y.

Cancer. 2001 Oct 15;92(8):2197-203.

PMID:
11596038
18.

Pleurectomy/decortication for palliation in malignant pleural mesothelioma: results of surgery.

Soysal O, Karaoğlanoğlu N, Demiracan S, Topçu S, Taştepe I, Kaya S, Unlü M, Cetin G.

Eur J Cardiothorac Surg. 1997 Feb;11(2):210-3.

PMID:
9080144
19.

Important prognostic factors in patients with malignant pleural mesothelioma, managed surgically.

Rusch VW, Venkatraman ES.

Ann Thorac Surg. 1999 Nov;68(5):1799-804.

PMID:
10585061
20.

Is pleurectomy and decortication superior to palliative care in the treatment of malignant pleural mesothelioma?

Zahid I, Sharif S, Routledge T, Scarci M.

Interact Cardiovasc Thorac Surg. 2011 May;12(5):812-7. doi: 10.1510/icvts.2010.256271. Epub 2011 Feb 22. Review.

PMID:
21345818

Supplemental Content

Support Center